Caribou Biosciences, Inc.
CRBU
$1.44
-$0.10-6.49%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -43.79% | 1.87% | 89.74% | 8.60% | -23.01% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -43.79% | 1.87% | 89.74% | 8.60% | -23.01% |
| Cost of Revenue | -31.60% | -41.99% | -21.83% | -26.36% | -21.95% |
| Gross Profit | 30.30% | 45.10% | 29.99% | 28.86% | 21.84% |
| SG&A Expenses | -24.10% | -17.14% | -18.20% | -6.54% | -9.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -29.55% | -36.65% | -20.90% | -21.52% | -18.89% |
| Operating Income | 28.48% | 38.76% | 26.81% | 23.11% | 18.56% |
| Income Before Tax | 55.11% | 37.27% | 23.83% | 20.57% | -43.51% |
| Income Tax Expenses | -- | -- | -6,011.11% | -- | -- |
| Earnings from Continuing Operations | 55.11% | 37.27% | 25.36% | 20.57% | -43.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 55.11% | 37.27% | 25.36% | 20.57% | -43.51% |
| EBIT | 28.48% | 38.76% | 26.81% | 23.11% | 18.56% |
| EBITDA | 27.87% | 38.61% | 26.32% | 22.37% | 19.66% |
| EPS Basic | 58.66% | 39.35% | 28.02% | 22.98% | -39.35% |
| Normalized Basic EPS | 46.66% | 39.38% | 26.54% | 22.95% | -8.05% |
| EPS Diluted | 58.66% | 39.35% | 28.02% | 22.98% | -39.35% |
| Normalized Diluted EPS | 46.66% | 39.38% | 26.54% | 22.95% | -8.05% |
| Average Basic Shares Outstanding | 8.55% | 3.43% | 3.70% | 3.14% | 2.98% |
| Average Diluted Shares Outstanding | 8.55% | 3.43% | 3.70% | 3.14% | 2.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |